FDCC
IRLA

Foster Dykema Cabot & Co’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Foster Dykema Cabot & Co’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15
Closed -$281K – 97
2021
Q3 		$281K Buy
+15
New +$239K 0.04% 80

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Foster Dykema Cabot & Co's IRLA Position: Q4 2021 in Review

Foster Dykema Cabot & Co sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2021, closing a stake of 15 shares — an estimated $281K sold.

Foster Dykema Cabot & Co first reported a position in IRLA in Q3 2021 and held it in 1 quarter. The position peaked at $281K in Q3 2021. 98 funds tracked by Wall St. Rank hold IRLA as of Q4 2021.

  • Foster Dykema Cabot & Co reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Foster Dykema Cabot & Co sold 15 IRulya Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $281K.
  • Foster Dykema Cabot & Co first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Foster Dykema Cabot & Co's IRulya Therapeutics Inc. Common Stock position peaked at $281K in Q3 2021.
  • 98 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2021.

Based on Foster Dykema Cabot & Co's 13F filing for Q4 2021, filed 9 Feb 2022.